ArticleJournal of molecular histology2025
Evaluation of the effects of monosodium glutamate on the development of the cerebellum in chicken embryos.
Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Monosodium glutamate (MSG) is a globally used food additive in the modern diet. This study aimed to search the impact of varying doses of MSG administered on embryonic development of the cerebellum. A total of 410 fertilized chicken eggs were randomly assigned to five groups: an untreated control group, a vehicle control group, and groups receiving low-dose (0.12 mg/g egg), medium-dose (0.6 mg/g egg), and high-dose (1.2 mg/g egg) MSG, respectively. The test solutions were injected into the yolk of eggs through a sterile insulin injector. On the 15th, 18th, and 21st days of incubation, the eggs from each group were randomly opened, and six live embryos were obtained. Cerebellum samples of embryos from each group were taken. The number of Purkinje cells in the cerebellum demonstrated a reduction in MSG-treated groups by the 15th, 18th, and 21st days of incubation (p < 0.05). It was noted that the organization of Purkinje cells was irregular, and degeneration and necrosis were also observed in the MSG-treated groups. A notable decrease in the thickness of both the outer and inner granular layers was observed in the MSG-treated groups on the 15th, 18th, and 21st day of incubation. While molecular layer thickness increased on day 15 and 21, decreased on day 18 (p < 0.05). Total cortex thickness decreased significantly in MSG-treated groups. PCNA-positive cells in the cerebellum were found in Purkinje cells, molecular layer cells, and outer and inner granular layer cells. However, there was a decrease in PCNA ( +) cell density in MSG-treated groups (p < 0.05).
Indexed as
Identifiers
40696195What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.